Hemab Therapeutics Launches Initial Public Offering
MT Newswires Live
Apr 27
Hemab Therapeutics said Monday it has launched an initial public offering of about 11.8 million shares of common stock, with pricing estimated to be between $16 and $18 per share.
The company granted underwriters the option to purchase up to an additional 1.8 million shares at the initial public offering price.
Net proceeds from the offering will be used to initiate a planned phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia and report data from a phase 2 clinical trial of sutacimig in Factor VII deficiency, among others, the company said.
Hemab Therapeutics said it has applied to list its common stock on Nasdaq under the symbol "COAG."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.